US 11,866,789 B2
Targeted therapies for cancer
Sara Byron, Phoenix, AZ (US); Jessica Aldrich, Phoenix, AZ (US); John Carpten, Phoenix, AZ (US); David Craig, Phoenix, AZ (US); Mitesh Borad, Scottsdale, AZ (US); Alan Bryce, Scottsdale, AZ (US); Michael Barrett, Scottsdale, AZ (US); George Vasmatzis, Rochester, MN (US); and Keith Stewart, Scottsdale, AZ (US)
Assigned to The Translational Genomics Research Institute, Phoenix, AZ (US)
Filed by THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, Phoenix, AZ (US); and MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, Rochester, MN (US)
Filed on Aug. 25, 2021, as Appl. No. 17/411,447.
Application 17/411,447 is a continuation of application No. 15/735,289, granted, now 11,186,875, previously published as PCT/US2016/037292, filed on Jun. 13, 2016.
Claims priority of provisional application 62/174,950, filed on Jun. 12, 2015.
Prior Publication US 2022/0042112 A1, Feb. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01); G01N 33/574 (2006.01); A61K 39/395 (2006.01)
CPC C12Q 1/6886 (2013.01) [A61K 39/39558 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G01N 33/57496 (2013.01); G01N 2570/00 (2013.01); G01N 2800/52 (2013.01); G01N 2800/7028 (2013.01)] 26 Claims
 
1. A method of treating a patient with cholangiocarcinoma cancer, the method comprising the steps of:
analyzing a sample from a patient with cholangiocarcinoma cancer for a DNA translocation in chromosome 8 band 12 p;
identifying a RBPMS-NRG1 fusion event transcribed by the DNA translocation in chromosome 8 band 12 p having a breakpoint between the 5′ end of exon 5 of the RBPMS portion and the 3′ end of exon 2 of the NRG1 portion, wherein the NRG1 portion of the RBPMS-NRG1 fusion event retains a EGF-like domain on the NRG1 portion; and
administering to the patient, having the RBPMS-NRG1 fusion event, a treatment of a therapeutic agent comprising at least one EGFR inhibitor that is targeted for the EGF-like domain of the NRG1 portion of the RBPMS-NRG1 fusion event.